Issue Date: March 14, 2011
Renovo Slashes Jobs After Trial Failure
Renovo is reducing its staff by more than 100 people after negative Phase III clinical trial results for Juvista, an injectable solution of human active recombinant transforming growth factor β3 being developed to reduce scarring. Renovo, based in Manchester, England, employs about 110 people. The firm announced the trial results on Feb. 11. The decision to downsize is in response to a review of the results and confirmation that Shire, its commercialization partner for Juvista, has terminated a licensing agreement for the product.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society